Showing results (91-100 of 112) with videos related to
Sort By:
Pageof 12
The Lancet. Infectious Diseases|July 19, 2025
Human papillomavirus (HPV) type 16 and type 18 antibody concentrations after a single dose of bivalent HPV vaccine in girls aged 9-14 years compared with three doses of quadrivalent HPV vaccine in women aged 18-25 years in Costa Rica (PRIMAVERA): a non-randomised, open-label, immunobridging, non-inferiority trialBernal Cortés, Rebeca Ocampo, Carolina Porras, et al.The Lancet. Global Health|September 16, 2022
Comparing one dose of HPV vaccine in girls aged 9-14 years in Tanzania (DoRIS) with one dose of HPV vaccine in historical cohorts: an immunobridging analysis of a randomised controlled trialKathy Baisley, Troy J Kemp, Aimée R Kreimer, et al.NPJ Vaccines|March 30, 2022
HPV16 infection decreases vaccine-induced HPV16 antibody avidity: the CVT trialSabrina H Tsang, John T Schiller, Carolina Porras, et al.Human Vaccines & Immunotherapeutics|April 11, 2013
Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: results from the Costa Rica Vaccine TrialMahboobeh Safaeian, Troy J Kemp, David Yuanji Pan, et al.Vaccine|January 26, 2018
Evidence for single-dose protection by the bivalent HPV vaccine-Review of the Costa Rica HPV vaccine trial and future research studiesAimée R Kreimer, Rolando Herrero, Joshua N Sampson, et al.Journal of the National Cancer Institute|September 28, 2017
Durability of Protection Afforded by Fewer Doses of the HPV16/18 Vaccine: The CVT TrialMahboobeh Safaeian, Joshua N Sampson, Yuanji Pan, et al.Journal of the National Cancer Institute|October 3, 2014
Cigarette smoking and variations in systemic immune and inflammation markersMeredith S Shiels, Hormuzd A Katki, Neal D Freedman, et al.Journal of the National Cancer Institute|February 25, 2020
Durability of Cross-Protection by Different Schedules of the Bivalent HPV Vaccine: The CVT TrialSabrina H Tsang, Joshua N Sampson, John Schussler, et al.Plos One|January 10, 2013
HPV16 seropositivity and subsequent HPV16 infection risk in a naturally infected population: comparison of serological assaysShih-Wen Lin, Arpita Ghosh, Carolina Porras, et al.Human Vaccines & Immunotherapeutics|December 9, 2014
Comparison of adaptive and innate immune responses induced by licensed vaccines for Human PapillomavirusDouglas M Herrin, Emily E Coates, Pamela J Costner, et al.Pageof 12